Integra Lifesciences Holdings (IART) Accumulated Expenses (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Accumulated Expenses data on file, last reported at $58.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 57.76% year-over-year to $58.0 million; the trailing twelve-month figure through Mar 2026 stood at $58.0 million (down 57.76% YoY), and the FY2025 full-year result was $74.1 million, down 13.48% from the prior year.
• Accumulated Expenses eased to $58.0 million in Q1 2026, from $74.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $137.4 million in Q1 2025 to a low of $58.0 million in Q1 2026.
• A 5-year average of $92.3 million and a median of $85.4 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 106.58% in 2024 and plunged 57.76% in 2026, its largest moves.
• Tracing IART's Accumulated Expenses over 5 years: stood at $78.8 million in 2022, then fell by 4.21% to $75.5 million in 2023, then gained by 13.47% to $85.6 million in 2024, then retreated by 13.48% to $74.1 million in 2025, then decreased by 21.65% to $58.0 million in 2026.
• Business Quant data shows IART's Accumulated Expenses at $58.0 million in Q1 2026, $74.1 million in Q4 2025, and $132.9 million in Q3 2025.